Avenue Short Long Term Debt from 2010 to 2024

ATXI Stock  USD 3.71  0.31  9.12%   
Avenue Therapeutics' Short and Long Term Debt is decreasing with slightly volatile movements from year to year. Short and Long Term Debt is predicted to flatten to about 3.1 M. Short and Long Term Debt is the total of a company’s short-term and long-term borrowings. View All Fundamentals
 
Short and Long Term Debt  
First Reported
2010-12-31
Previous Quarter
3.5 M
Current Value
3.1 M
Quarterly Volatility
217.2 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Avenue Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Avenue Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 165.9 K, Depreciation And Amortization of 15.3 M or Interest Expense of 350.7 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.13. Avenue financial statements analysis is a perfect complement when working with Avenue Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Avenue Therapeutics Correlation against competitors.
For more detail on how to invest in Avenue Stock please use our How to Invest in Avenue Therapeutics guide.

Latest Avenue Therapeutics' Short Long Term Debt Growth Pattern

Below is the plot of the Short Long Term Debt of Avenue Therapeutics over the last few years. It is the total of a company’s short-term and long-term borrowings. Avenue Therapeutics' Short and Long Term Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Avenue Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Short Long Term Debt10 Years Trend
Slightly volatile
   Short Long Term Debt   
       Timeline  

Avenue Short Long Term Debt Regression Statistics

Arithmetic Mean3,779,573
Geometric Mean3,773,111
Coefficient Of Variation5.75
Mean Deviation134,606
Median3,848,000
Standard Deviation217,169
Sample Variance47.2B
Range781.6K
R-Value(0.60)
Mean Square Error32.4B
R-Squared0.36
Significance0.02
Slope(29,214)
Total Sum of Squares660.3B

Avenue Short Long Term Debt History

20243.1 M
20233.5 M
20163.8 M

Other Fundumenentals of Avenue Therapeutics

Avenue Therapeutics Short Long Term Debt component correlations

0.940.920.51-0.87-0.20.58-0.460.35-0.340.091.00.520.1-0.1-0.1-0.050.12
0.941.00.6-0.95-0.490.42-0.60.62-0.64-0.160.940.60.33-0.35-0.350.2-0.13
0.921.00.62-0.94-0.510.41-0.620.64-0.66-0.190.920.620.38-0.37-0.370.26-0.16
0.510.60.62-0.71-0.750.3-0.960.77-0.48-0.220.511.00.63-0.72-0.720.42-0.17
-0.87-0.95-0.94-0.710.63-0.420.69-0.730.660.11-0.87-0.71-0.470.540.53-0.190.08
-0.2-0.49-0.51-0.750.630.080.82-0.990.820.55-0.2-0.74-0.860.920.93-0.570.52
0.580.420.410.3-0.420.08-0.240.00.130.160.580.3-0.25-0.14-0.14-0.30.17
-0.46-0.6-0.62-0.960.690.82-0.24-0.850.550.46-0.46-0.96-0.640.780.78-0.470.42
0.350.620.640.77-0.73-0.990.0-0.85-0.86-0.550.350.770.81-0.9-0.90.57-0.52
-0.34-0.64-0.66-0.480.660.820.130.55-0.860.46-0.34-0.48-0.650.690.69-0.660.44
0.09-0.16-0.19-0.220.110.550.160.46-0.550.460.09-0.2-0.40.470.49-0.491.0
1.00.940.920.51-0.87-0.20.58-0.460.35-0.340.090.520.1-0.1-0.1-0.050.12
0.520.60.621.0-0.71-0.740.3-0.960.77-0.48-0.20.520.63-0.72-0.710.41-0.16
0.10.330.380.63-0.47-0.86-0.25-0.640.81-0.65-0.40.10.63-0.71-0.720.48-0.38
-0.1-0.35-0.37-0.720.540.92-0.140.78-0.90.690.47-0.1-0.72-0.711.0-0.490.44
-0.1-0.35-0.37-0.720.530.93-0.140.78-0.90.690.49-0.1-0.71-0.721.0-0.490.46
-0.050.20.260.42-0.19-0.57-0.3-0.470.57-0.66-0.49-0.050.410.48-0.49-0.49-0.48
0.12-0.13-0.16-0.170.080.520.170.42-0.520.441.00.12-0.16-0.380.440.46-0.48
Click cells to compare fundamentals

About Avenue Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Avenue Therapeutics income statement, its balance sheet, and the statement of cash flows. Avenue Therapeutics investors use historical funamental indicators, such as Avenue Therapeutics's Short Long Term Debt, to determine how well the company is positioned to perform in the future. Although Avenue Therapeutics investors may use each financial statement separately, they are all related. The changes in Avenue Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Avenue Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Avenue Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Avenue Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Short and Long Term Debt Total6.8 M5.4 M
Short and Long Term Debt3.5 M3.1 M

Currently Active Assets on Macroaxis

Additional Information and Resources on Investing in Avenue Stock

When determining whether Avenue Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Avenue Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Avenue Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Avenue Therapeutics Stock:
Check out the analysis of Avenue Therapeutics Correlation against competitors.
For more detail on how to invest in Avenue Stock please use our How to Invest in Avenue Therapeutics guide.
You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avenue Therapeutics. If investors know Avenue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avenue Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.76)
Earnings Share
-1.1 K
Return On Assets
(1.26)
Return On Equity
(5.35)
The market value of Avenue Therapeutics is measured differently than its book value, which is the value of Avenue that is recorded on the company's balance sheet. Investors also form their own opinion of Avenue Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Avenue Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avenue Therapeutics' market value can be influenced by many factors that don't directly affect Avenue Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avenue Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avenue Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avenue Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.